胰激肽原酶联合赖诺普利治疗早期糖尿病肾病

目的探讨胰激肽原酶联合赖诺普利治疗早期糖尿病肾病的疗效。方法选择早期糖尿病肾病患者（102例）给以降血糖药物和赖诺普利片治疗,随机分为对照组（49例）和加用胰激肽原酶片治疗组（53例）疗程6个月。治疗前后分别测定24 h尿微量白蛋白、空腹血糖、糖化血红蛋白（HbA1C）、血肌酐、纤维蛋白原、血钾及血压。结果治疗后两组所有观测指标均较治疗前降低（P〈0.05）。24 h尿微量白蛋白下降程度治疗组（P〈0.01）较对照组（P〈0.05）更显著,两组间的差异具有统计学意义（P〈0.05）。结论提示胰激肽原酶联合赖诺普利治疗早期糖尿病肾病较单用赖诺普利能更有效地减少尿白蛋白的排泄。

The Therapy of Early Diabetic Nephropathy with Pancreatic Kininogenase Combined with Lisinopril

Objective To study the therapeutic effects of early diabetic nephropathy with pancreatic kininogenase combined with lisinopril.Methods 102 patients with early diabetic nephropathy were selected to be treated with hypoglycemic and lisinopril drugs,and randomly divided into control group(49 cases)and treatment group(53 cases)with pancreatic kininogenase for 6 months.Respective determination of 24 hours urine microalbumin,fasting blood glucose,glycosylated hemoglobin,creatinine,fibrinogen,potassium and blood pressure were done before and after treatment.Results All the observed values of both group decreased after treatment compared with that before treatment(P<0.05).Compared with control group(P<0.05),the value degree of 24 hours urine microalbumin were markedly decreased in treatment group(P<0.01)and the difference between two groups(P<0.01)had statistical significance.Conclusion Our study suggests that more excretion of 24 hours urine microalbumin were decreased in early diabetic nephropathy with treatment of pancreatic kininogenase combined with lisinopril than the alone lisinopril use.